Publikationen in Zusammenarbeit mit Forschern von University Medical Center Utrecht (69)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  3. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  4. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)

    The Lancet Psychiatry, Vol. 10, Núm. 3, pp. 197-208

  5. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  6. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

  7. Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database

    Peritoneal Dialysis International, Vol. 43, Núm. 1, pp. 23-36

  8. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

    Psychological medicine, Vol. 53, Núm. 15, pp. 7418-7427

  9. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  10. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

  11. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3396-3405